Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health

Johnson & Johnson

Shares of CVS Health have been beaten down in response to lower COVID-related revenue, but this is only a temporary setback. Medtronic shares offer an above-average dividend yield, and its payout has risen for 45 consecutive years.

3 Top S&P 500 Stocks Near 52-Week Lows That Look Like Bargains Now

DaVita

New, independent kidney health technology company will combine expertise from two industry leaders to drive care transformation DUBLIN and DENVER , April 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT) and DaVita Inc. (NYSE: DVA) today announced the launch of Mozarc Medical—an independent new company committed to reshaping kidney health and driving patient-centered technology solutions. "Mozarc Medical's focus will be on meaningful and innovative kidney health technologies that improve the overall patient experience and increase access to care globally," said Ven Manda, CEO of Mozarc Medical.

Medtronic, DaVita launch Mozarc Medical, aimed at introducing new solutions for patients with kidney failure

Abbott Labs

Automatic Data Processing

Clorox

Ecolab

Essex Property Trust

Hormel Foods

Nordson

Realty Income Corp

Sherwin-Williams

S&P Global

Stanley Black & Decker

Sysco

T. Rowe Price Group

V.F.

Walgreens

Exxon Mobil

NOBL gave up a big chunk of its January gains in February, finishing the month down 2.36%. March has seen the ETF tumble some more as it's down 1.88% through 3/29. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term.

My Best Dividend Aristocrats For April 2023

Medtronic and ExxonMobil are two top dividend stocks that have been raising their payouts for 40-plus years. Medtronic's business should pick up this year now that China has abandoned its restrictive COVID lockdowns.

2 Dividend Growth Stalwarts With Impressive Streaks Going and Yield Twice That of the S&P 500

UBS hit Medtronic PLC (NYSE:MDT) with a downgrade to "sell" from "buy," with a steep price-target cut to $79 from $127.

Medtronic Stock Slammed With UBS Downgrade

Gastroenterology AI biotech Medtronic (NYSE: MDT) has maintained a HOLD rating since Sept 1, 2022, but a focused strategy could change that very soon. The company has recently revealed a plan to trim some personnel that should, first of all, cut some expenses.

Will the Big Shifts at Medtronic Boost Revenue, Rating?

Mobileye Global Inc

Schrodinger 

The Fourth Industrial Revolution refers to the use of multiple advanced technologies, including “artificial intelligence (AI), robotics, [and] the Internet of Things (IoT).” Also in the mix are “faster computer processing,” “biotechnology,” and “Energy capture, storage, and transmission,” Salesforce reported.

3 Tech Stocks to Buy for the Fourth Industrial Revolution

Henry Schein

Stryker

Syneos Health

MedTech player like Medtronic (MDT) are integrating artificial intelligence (AI) capabilities to aid therapeutic and diagnostic applications.

MedTech Bigwigs in Spotlight as AI Revolutionizes Healthcare

Texas Instruments

Economies are complex, but a simple surety is that recessions happen with some regularity. It can be tough to stay invested when everything around you looks like it is falling apart.

Recessions Don't Have to Be Scary for Your Portfolio. Here's Why.

DUBLIN , March 23, 2023 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering (the "Offering") of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000,000 principal amount of 4.50% senior notes due 2033 (collectively, the "Notes").

Medtronic Announces Pricing of $2.0 Billion of Senior Notes

Medtronic's (MDT) GI Genius intelligent endoscopy module is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.

Medtronic (MDT) to Enhance AI Innovation With New Platform

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Why Is Medtronic (MDT) Down 6.1% Since Last Earnings Report?

A strategic collaboration with Cosmo Pharmaceuticals   and NVIDIA delivers the GI Genius™ AI Access™ platform designed to accelerate AI innovation for healthcare. DUBLIN , March 22, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced Cosmo Pharmaceuticals  and NVIDIA plan to integrate NVIDIA's AI technologies into the GI Genius™ intelligent endoscopy module — the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.

Medtronic to boost AI innovation with new platform introduction

Medtronic's most recent quarter was underwhelming, showing no revenue growth. However, the medical device maker still has plenty of opportunities out there.

This Future Dividend King Is Trading Near Its 52-Week Low

Federal Realty Investment Trust

Procter & Gamble

As a human being, I am inherently emotional just like you. The biggest problem that most investors will ever face is their own emotional swings.

I'll Never Make This Bear Market Mistake Again

Medtronic's (MDT) Affera Mapping and Ablation System is intended to treat atrial arrhythmias.

Medtronic's (MDT) Affera Ablation System Gets CE Mark

Accenture Plc

Aptiv Holdings Ltd

Eaton

Horizon Pharma

Ahead of St. Patrick's Day, when everyone is Irish for a day, investors may be interested in trying their luck with companies headquartered on the Emerald Isle.

5 Stocks Gurus Are Trying Their Luck With for St. Patrick's Day

Cincinnati Financial

Lockheed Martin

PepsiCo

UnitedHealth Group

High uncertainty may continue to loom over the stock market, but that doesn't mean you need to stay on the sidelines. Instead, keep your eyes on the long-term, with solid additions to your portfolio, such as the best blue-chip stocks to buy and hold.

7 Blue-Chip Stocks to Buy and Hold for Decades

First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform DUBLIN , March 15, 2023 /PRNewswire/ -- Medtronic (NYSE:MDT) announced today that it has received CE (Conformité Européenne) Mark for the Affera™ Mapping and Ablation System, which includes the Sphere-9™ Catheter and the Affera™ Prism-1 Mapping Software. Together, the full system creates a new paradigm in electrophysiology through the unique integration of the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and high density (HD) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and provides real-time feedback through its intuitive mapping and navigation software.

Medtronic receives CE Mark approval for Affera™ Mapping and Ablation System to treat atrial arrhythmias

Verizon

Medtronic (NYSE: MDT) and Verizon (NYSE: VZ) are 2 high-yielding stocks that investors who like to sleep at night should consider. They offer yield and value, and they also have robust upside potential.

2 High-Yield Sleep-At-Night Stocks To Buy And Forget About

City Office REIT

Kellogg

Newmont Mining

Pfizer

Rio Tinto plc Sponsored

Vale S.A.

With markets getting dragged down by another financial crisis, investors should seek safety.  In fact, one of the best places for that is in undervalued dividend stocks.

7 Undervalued Dividend Stocks for Your Must-Buy List

AbbVie

Becton, Dickinson and Co.

Cardinal Health

Roper Technologies

West Pharmaceutical Services

While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.

Healthcare Stocks With at Least 30 Years of Dividend Increases

News for Medtronic Stock (MDT)